IL6R and non-small cell lung carcinoma: As an anti-IL6R antibody, tocilizumab has been FDA-approved for the treatment of rheumatic disease and has recently been evaluated for the treatment of solid tumors in clinical trials.42–44 Our study reconfirmed that targeting IL6R could reduce NSCLC-BM.45 Considering the direct role of tocilizumab on lung cancer cells, we explored the effect of tocilizumab in inhibiting brain metastases following microglial depletion with PLX5622.